ORGN 65 |
| We have exploited the frequent over-expression of folate receptors (FR) on cancer cells to target folate-linked drugs specifically to malignant cells, thereby avoiding collateral toxicity to healthy cells. Although i) protein toxins, ii) chemotherapeutic agents, iii) gene therapy vectors, iv) antisense oligonucleotides, v) radioimaging agents, vi) MRI contrast agents, vii) liposomes with entrapped drugs, viii) radiotherapeutic agents, ix) dendrimers, x)siRNAs, xi)immunotherapeutic agents, and xiii) enzyme constructs for prodrug therapy have all been successfully delivered into tumor cells, most recent effort has been devoted to optimization of radioimaging, chemotherapeutic and immunotherapeutic agents for human applications. Current clinical trials of three folate-linked drugs demonstrate that the folate receptor-targeting strategy holds great promise for increasing drug potency while reducing drug toxicity. A brief summary of both preclinical and clinical developments with these targeted agents will be presented, and the strengths and weakness of the general FR targeting strategy will be described. |
|
New Molecular Strategies for Tumor-Targeting Drug Delivery
1:25 PM-5:20 PM, Sunday, August 19, 2007 BCEC -- 253 A/B/C, Oral
Division of Organic Chemistry |